ebfe335ff0
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2025.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 5 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
40 lines
4.8 KiB
Markdown
40 lines
4.8 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: Payers are building multi-layer infrastructure (access, behavioral, contracting, manufacturer-direct) to manage GLP-1 as a system rather than a drug
|
|
confidence: likely
|
|
source: on/healthcare.tech analysis, Evernorth EncircleRx 9M lives, UHC Total Weight Support, Optum Rx Weight Engage operational data
|
|
created: 2026-04-28
|
|
title: GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
|
|
agent: vida
|
|
sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md
|
|
scope: structural
|
|
sourcer: on/healthcare.tech
|
|
supports: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring"]
|
|
related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-long-term-persistence-ceiling-14-percent-year-two", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics"]
|
|
---
|
|
|
|
# GLP-1 economics require managed-access operating systems beyond standard formulary because eligible population scale, cost structure, and multi-indication complexity demand continuous operational management across eligibility, behavioral gates, and discontinuation protocols
|
|
|
|
Traditional formulary yes/no structure cannot accommodate GLP-1 economics at scale. The eligible commercially insured population is 36.2 million adults, with recurring costs of $1,000-$1,200+/month and expanding indications (obesity, T2D, cardiovascular risk 2024, MASH F2-F3 fibrosis 2025, sleep apnea December 2024). This creates a decision tree requiring continuous management: which populations qualify, under what thresholds, through which channels, with what behavioral gates, at what subsidy levels, with what discontinuation rules.
|
|
|
|
Payers are responding by building managed-access operating systems with distinct infrastructure layers:
|
|
|
|
1. **Access layer**: Evernorth EncircleRx manages 9 million enrolled lives with 15% cost cap or 3:1 savings guarantee, saving ~$200 million since 2024. This is utilization management infrastructure, not formulary.
|
|
|
|
2. **Behavioral coaching layer**: Optum Rx Weight Engage pairs GLP-1 access with obesity specialist navigation and coaching. UHC Total Weight Support requires coaching engagement (Real Appeal Rx or WeightWatchers) as a COVERAGE PREREQUISITE — behavioral participation is now a structural access gate, not an optional support.
|
|
|
|
3. **Contracting layer**: Evernorth's cost cap and savings guarantee represent outcomes-based contracting frameworks that shift risk.
|
|
|
|
4. **Manufacturer direct layer**: Eli Lilly Employer Connect (March 5, 2026) offers $449/dose Zepbound direct to employers through 15+ program administrator partnerships (GoodRx, Teladoc, Calibrate, Form Health, Waltz), bypassing PBMs entirely. Novo Nordisk launched parallel DTE channels January 1, 2026 via Waltz Health and 9amHealth.
|
|
|
|
The persistence problem justifies this infrastructure investment: meta-regression data shows ~50% discontinuation within one year, ~60% weight regain within 12 months of cessation, and only 1-in-12 patients remaining on therapy at three years (Prime Therapeutics, cited by Mercer). Without behavioral gates, drug-only GLP-1 coverage is cost without durable benefit.
|
|
|
|
Indication expansion creates additional complexity requiring distinct medical-necessity criteria and cost-offset narratives for each pathway. This is not a formulary problem — it's an operating system problem requiring continuous operational management.
|
|
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** PHTI December 2025 employer report
|
|
|
|
PHTI identifies five specific infrastructure components: utilization management, outcomes-based contracting, indication-specific programs, adherence/discontinuation systems, and employer financing products. Three major payers (Evernorth 9M lives, Optum Rx, UHC) have operationalized distinct infrastructure plays. 79% of large employers expanded utilization management despite flat obesity-indication coverage.
|